CD30+皮肤T细胞淋巴瘤并发大疱性类天疱疮

报告1例CD30+皮肤T细胞淋巴瘤并发大疱性类天疱疮.患者男,77 岁.因躯干四肢皮疹伴偶痒3 个月入院.皮损和淋巴结组织病理及免疫组化检查提示CD30+皮肤T细胞淋巴瘤.患者在入院期间出现局限性水疱,组织病理及免疫荧光检查证实为大疱性类天疱疮.给予泼尼松30 mg/d 口服;重组人干扰素α-2b 300万U 肌内注射,隔日1 次,皮损较前减轻.     

原发性皮肤弥漫性大B细胞淋巴瘤

报告1例原发性皮肤弥漫性大B细胞淋巴瘤.患者男,87岁.右下肢结节1年余.皮肤科检查:右下肢内侧可见8 cm×8 cm肿块,周围可见数个大小不等黄豆至蚕豆大的散在褐色结节.皮损组织病理示:表皮萎缩,真皮内可见单一核细胞呈团块状浸润,细胞体积大,胞质丰富,胞核淡染,并见核异形性和较多核分裂象.免疫组化结果:Bcl-2(+)、MUM-1(+).诊断:原发性皮肤弥漫性大B细胞淋巴瘤(腿型)(PCLBCL-LT).     

原发性皮肤弥漫性大B细胞淋巴瘤,腿型

报告1例原发性皮肤弥漫性大B细胞淋巴瘤,腿型.患者女,77岁.因右胫前多发暗红色斑块和结节3个月入院.皮损组织病理检查示:肿瘤细胞在真皮内弥漫性浸润性生长,侵及皮下组织,肿瘤细胞体积增大,形态不规则,细胞核大深染,核分裂象多见.免疫组化染色示:瘤细胞CD20(+),CD79a(+),Bcl-2(+),MuM-1(+).诊断:原发性皮肤弥漫性大B细胞淋巴瘤,腿型.通过CD20单克隆抗体加CHOP化疗方案治疗,病情明显好转.     

儿童大疱性类天疱疮

报告1例儿童大疱性类天疱疮.患儿男,18个月.2个月前躯干和双下肢皮肤出现紧张性水疱、大疱,尼氏征阴性,外用糖皮质激素治疗效果不佳.皮损组织病理检查示表皮下水疱;卣接免疫荧光示:lgG、C3沉积于基膜,间接免疫荧光示抗表皮基膜抗体阳性.诊断为儿童大疱性类天疱疮,予以口服泼尼松治疗后痊愈.     

非霍奇金B细胞淋巴瘤伴发大疱性类天疱疮1例

目的报道大疱性类天疱疮的临床及病理特征、治疗及预后情况。方法对1例非霍奇金淋巴瘤合并大疱性类天疱疮的临床特点及病理特征,结合国内外文献进行分析。结果该病例通过皮肤病理活检及免疫荧光得到诊断并给予中西医结合的积极治疗。结论非霍奇金淋巴瘤合并大疱性类天疱疮的早期诊断,结合中药治疗,可以控制病情,改善预后。     

大疱性类天疱疮合并原发性腹膜后弥漫大B细胞淋巴瘤1例

患者男,77岁。躯干、四肢反复红斑、水疱1年余,加重10d,确诊为大疱性类天疱疮。患者发病4年后体检时发现腹膜后肿物,外科手术切除肿物后组织病理显示淋巴样细胞弥漫性浸润,免疫组化示CD20(+),PAX-5(+),Bcl-6(灶+),MUM-1(+),Ki-67(90%+)。诊断:原发性腹膜后弥漫大B细胞淋巴瘤。     

原发性皮肤弥漫性大B细胞淋巴瘤并发嗜酸性粒细胞增多

报告1例原发性皮肤弥漫性大B细胞淋巴瘤并发嗜酸性粒细胞增多.患者男,71岁.伞身散在红斑、丘疹及小结节,外周血嗜酸性粒细胞计数增多.第1次行皮损组织病理检查示嗜酸性粒细胞增多,予以精皮质激素治疗后皮损消退,但外周血嗜酸性粒细胞计数持续增多.发病近4个月,结节再次出现,第2次组织病理检查示真皮及皮下组织内弥漫淋巴细胞浸润,多数浸润细胞核大,染色深,核分裂象易见.免疫组化染色:大的肿瘤细胞CD20、CD79a、Bcl-2均(+).诊断:原发性皮肤弥漫性大B细胞淋巴瘤.给予环磷酰胺、长春地辛、呲喃阿霉素、泼尼松(CHOP)方案化疗后皮损改善不明显.     

原发性皮肤弥漫大B细胞淋巴瘤（腿型）一例

报告1例原发性皮肤弥漫性大B细胞淋巴瘤（腿型）。患者男,51岁。右小腿出现多个红色结节5个月,组织病理检查：表皮和真皮之间见无细胞浸润带,真皮内淋巴样细胞浸润,细胞体积大,异形。肿瘤细胞CD20（++）,Bcl-6(+),Bcl-2(+),Pax-5(+),Ki-67 50％-75％(+),CD79a(+),MUM-1（+）,CD10（-）,诊断为原发性皮肤弥漫性大B细胞淋巴瘤（腿型）,给予CD20单克隆抗体加CHOP方案治疗,病情好转。     

大疱性类天疱疮抗原1和2在大疱性类天疱疮并发神经系统损害中的作用

大疱性类天疱疮可见于多种神经系统疾病患者,二者并发的机制尚不清楚.动物研究证实鼠大疱性类天疱疮抗原(BPAG)1至少存在3种亚型:皮肤亚型、神经业型和肌肉亚型.BPAG2除在皮肤有表达外,在人脑神经元也有广泛表达.有可能神经系统病变导致BPAG1和BPAG2神经亚型暴露于免疫系统,产生拮抗神经亚型的抗体,与皮肤亚型发生免疫反应及交叉反应,导致大疱性类天疱疮发生.     

婴儿大疱性类天疱疮1例

婴儿男,6月大时出现全身红斑、水疱和大疱,皮损组织病理可见真皮内嗜酸性细胞浸润,直接及间接免疫荧光显示:IgG基底膜带线状沉积。诊断:婴儿大疱性类天疱疮。糖皮质激素治疗有效。1岁以内婴儿大疱性类天疱疮国内报道少见。     

Cutaneous diffuse large B-cell lymphoma of the leg associated with chronic lymphedema

Development of malignant tumors is a rare but well known complication in chronic lymphedema (CL). We report herein a cutaneous diffuse large B-cell lymphoma of the leg associated with CL. An 89-year-old man presented with multiple cutaneous lesions on his right limb that showed a CL. Dermatological examination disclosed multiple violaceous, firm, slightly infiltrated nodules on the anterior aspect of the leg and the dorsum and sole of the foot. A biopsy of one nodule of the leg disclosed a diffuse large B-cell lymphoma, type of the legs. There was no evidence of lymphadenopathy on computed tomography (CT) scans of the chest, abdomen, and pelvis. A bone marrow aspiration and biopsy showed normal results. The patient was treated with local radiotherapy at a dose of 40 Gy, obtaining a highly significant, almost complete, clinical remission. A literature search identified 11 additional cases of primary cutaneous lymphoma associated with CL. An inadequate lymphatic drainage may make the lymphedematous region an immunologically vulnerable area, predisposing to neoplasia.     

原发性皮肤弥漫性大B细胞淋巴瘤（腿型）二例并文献复习

弥漫性大B细胞淋巴瘤（腿型）是皮肤B细胞淋巴瘤的一个罕见亚型，具有特征性的临床、病理、免疫组化及演变特征。本文报道2例原发性皮肤弥漫性大B细胞淋巴瘤（腿型）并复习相关文献。     

Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin’s lymphoma

The case of a 44-year-old man with a primary cutaneous large B-cell non-Hodgkin’s lymphoma of the scalp is reported. His mother died of gastric lymphoma and his sib brother is in a 20-year remission of T-cell lymphoma. The patient presented with a 16-year history of occipital and parietal alopecia and a recently worsening scalp rash. The histopathology and immunohistochemistry performed in April 2006 indicated a bcl-6+, MUM− and bcl-2−, primary cutaneous follicle center B-cell non-Hodgkin’s lymphoma, with an aggressive transformation to a diffuse large B-cell lymphoma. Bone marrow biopsy and CT chest, abdomen, and pelvis were negative for systemic lymphoma. The patient had an excellent clinical and histological resolution following 8 cycles of rituximab and CHOP protocol immunochemotherapy, and remains in complete remission until now. The protracted indolent phase of the disease, the familial history of lymphoma, the histological aggressive features and the patient’s excellent response to immunochemotherapy all contribute to a very unusual manifestation of this disease.     

Primary cutaneous spindle cell B-cell lymphoma with multiple figurate erythema-like manifestation

We report a 68-year-old Korean man presenting with asymptomatic erythematous polycyclic annular firm plaques on his back that spread to the right shoulder. Histopathologic examination showed dense, diffuse infiltrates involving the entire dermis, consisting of atypical lymphocytes with many centrocytes and a few centroblasts. Spindle-shaped cells with elongated, twisted nuclei containing dispersed chromatin were also seen. Immunohistochemical analysis showed that all of the cells were strongly positive for CD20, CD21, CD79a and CD45, while they were negative for CD3, CD5, CD10, CD23, CD35, CD43, CD45RO and CD68. The spindle cells were also negative for smooth-muscle actin, desmin, S-100 and CD34. They consistently expressed nuclear bcl-6, but did not express bcl-2, multiple myeloma-1 and p16. We diagnosed him with primary cutaneous spindle cell B-cell lymphoma (PCSBCL) and treated him with six cycles of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) chemotherapy; his skin lesions disappeared completely. Immunohistochemical profiles suggest that PCSBCL is a variant of primary cutaneous follicle center lymphoma.     

Linfoma cutáneo primario difuso de células grandes-tipo pierna con regresión espontánea

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL LT) accounts for approximately 20% of all primary cutaneous B-cell lymphomas and tends to present as infiltrated nodules, tumors, and plaques on the legs in the elderly. Unlike other primary cutaneous large B-cell lymphomas, it has a poor prognosis and tends to require treatment with systemic chemotherapy.We present the case of an 82-year-old patient with a 1-year history of nodules and plaques on her right leg. Biopsy led to a diagnosis of PCLBCL LT and the lesions resolved without treatment within 1 month of the first visit. This is an atypical course of PCLBCL LT and we believe that it is the first such case to be reported in the literature.     

Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases

OBJECTIVES: To describe clinicopathologic features and to identify prognostic factors in a large series of primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL LT), as defined in the recent World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas. DESIGN: Retrospective multicenter study from the French Study Group on Cutaneous Lymphomas. SETTING: Nineteen departments of dermatology in 10 regions of France. PATIENTS: Sixty patients with a PCLBCL LT included in the registry of the French Study Group on Cutaneous Lymphomas. MAIN OUTCOME MEASURES: Age, sex, outcome, therapy, B symptoms, cutaneous extent, number of lesions, location (leg vs nonleg), serum lactate dehydrogenase level, and MUM-1 and Bcl-2 expression were recorded. Disease-specific survival was used as the main end point. Prognostic factors were identified using a Cox proportional hazards model. RESULTS: Primary cutaneous diffuse large B-cell lymphoma, leg type is characterized by a predilection for the leg (72%), a high proportion of Bcl-2 expression (85%), an advanced age at onset (mean age, 76 years), and frequent relapses and extracutaneous dissemination. The overall 5-year disease-specific survival rate was 41%. Location on the leg and multiple skin lesions were predictive of death in multivariate analysis. Although no variable related to therapy was significantly associated with survival, patients recently treated with combinations of anthracycline-containing chemotherapies and rituximab had a more favorable short-term outcome. CONCLUSIONS: Primary cutaneous diffuse large B-cell lymphoma, leg type is a distinct entity with a poor prognosis, particularly in patients with multiple tumors on the legs. Despite the advanced age of many patients, the prognosis could be improved with combinations of anthracycline-containing chemotherapies and rituximab.     

Rituximab in cutaneous B-cell lymphoma: a report of two cases

We report two patients with primary cutaneous B-cell lymphoma who were treated with rituximab, a new anti-CD20 monoclonal antibody. The first patient, who had a diffuse large B-cell lymphoma of the lower leg, achieved an 85% improvement. The second patient, who had a primary cutaneous B-cell lymphoma, which had undergone high-grade transformation and systemic spread, achieved a minor response of approximately 30%. Both patients subsequently relapsed. The first patient achieved complete clearance with a second course of rituximab given with systemic chemotherapy, but again relapsed. Treatment with rituximab has been reported to produce response rates of 48% in relapsed systemic low-grade or follicular lymphoma, but there are no previous reports of the use of rituximab in primary cutaneous B-cell lymphoma.     

Comparative genomic hybridization analysis of cutaneous large B-cell lymphomas

The aim of the present study was to identify genetic aberrations in a series of patients with cutaneous large B-cell lymphoma (LBCL) using comparative genomic hybridization (CGH). Eighteen consecutive patients with primary (13 patients) (PCLBCL) and secondary (five patients) (SCLBCL) cutaneous large B-cell lymphoma were included in the study. Nine cases corresponded to PCLBCL leg type and four cases primary cutaneous follicle centre-cell lymphoma (PCFCL). Chromosomal imbalances (CIs) were detected in 14 of 18 samples (77.8%). All of nine cases with PCLBCL leg type and two of four cases with PCFCL showed CIs (100% and 50%, respectively). Regarding SCLBCL, in three of five cases (60%), CIs were detected. The most frequently detected gains involved 2q, 5q, 3 and 7q and amplifications affected 18, 12 and 13. Frequent losses were found in 17p. In PCLBCL leg type, the most frequent gains involved 2q and 7q, amplifications were localized in chromosomes 12, 13 and 18 and losses affected chromosomes 17p and 19. In PCFCL, gains located in 3q, 4 and 7q were found. Our study seems to confirm clear-cut differences between primary cutaneous LBCL and nodal diffuse LBCL, and it suggests the presence of genotypic differences between cases of PCLBCL leg type and cases of PCFCL.